Table 2.
Variables | All patients | miR-182 expression | P value | |
---|---|---|---|---|
(n = 36) | lowa | higha | ||
Age (years) | ||||
≤55 | 12 | 7 | 5 | 0.725 |
>55 | 24 | 11 | 13 | |
Gender | ||||
Male | 28 | 13 | 15 | 0.691 |
Female | 8 | 5 | 3 | |
Size of tumor (cm) | ||||
≤5 | 16 | 12 | 4 | 0.018* |
>5 | 20 | 6 | 14 | |
Number of tumor | ||||
Single | 20 | 12 | 9 | 0.5 |
Multiple | 16 | 6 | 9 | |
Portal vein invasion | ||||
Negative | 25 | 16 | 9 | 0.027* |
Positive | 11 | 2 | 9 | |
TNM staging | ||||
I, II | 21 | 13 | 8 | 0.176 |
III | 15 | 5 | 10 | |
Grade | ||||
Well + Moderate | 27 | 15 | 12 | 0.09 |
Poor | 9 | 3 | 6 | |
AFP (ng/ml) | ||||
≤400 | 10 | 6 | 4 | 0.711 |
>400 | 26 | 12 | 14 |
For analysis of correlation between miR-182 expression and clinical features, fisher exact tests were used. Results were considered statistically significant at P <0 .05 *
aThe median expression level was used as the cut-off. Low expression of miR-182 in 18 patients was classified as values below the 50th percentile. High miR-182 expression in 18 patients was classified as values above the 50th percentile